Claus Kremoser

Heidelberg, BW, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications

An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial.

An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial.

Journal: Nature medicine
Published: June 18, 2025

Development of Cilofexor, an Intestinally-Biased Farnesoid X Receptor Agonist, for the Treatment of Fatty Liver Disease.

Development of Cilofexor, an Intestinally-Biased Farnesoid X Receptor Agonist, for the Treatment of Fatty Liver Disease.

Journal: The Journal of pharmacology and experimental therapeutics
Published: August 24, 2023

Free Deoxycholic Acid Exacerbates Vascular Calcification in CKD through ER Stress-Mediated ATF4 Activation.

Free Deoxycholic Acid Exacerbates Vascular Calcification in CKD through ER Stress-Mediated ATF4 Activation.

Journal: Kidney360
Published: August 23, 2021

FXR agonists for NASH: How are they different and what difference do they make?

FXR agonists for NASH: How are they different and what difference do they make?

Journal: Journal of hepatology
Published: March 22, 2021

The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model.

The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model.

Journal: Biomedicines
Published: December 10, 2020

Nonsteroidal FXR Ligands: Current Status and Clinical Applications.

Nonsteroidal FXR Ligands: Current Status and Clinical Applications.

Journal: Handbook of experimental pharmacology
Published: June 15, 2019

Cold-induced conversion of cholesterol to bile acids in mice shapes the gut microbiome and promotes adaptive thermogenesis.

Cold-induced conversion of cholesterol to bile acids in mice shapes the gut microbiome and promotes adaptive thermogenesis.

Journal: Nature medicine
Published: June 27, 2016

Intestinal Farnesoid X Receptor Controls Transintestinal Cholesterol Excretion in Mice.

Intestinal Farnesoid X Receptor Controls Transintestinal Cholesterol Excretion in Mice.

Journal: Gastroenterology
Published: June 20, 2016

Novel substituted isoxazole FXR agonists with cyclopropyl, hydroxycyclobutyl and hydroxyazetidinyl linkers: Understanding and improving key determinants of pharmacological properties.

Novel substituted isoxazole FXR agonists with cyclopropyl, hydroxycyclobutyl and hydroxyazetidinyl linkers: Understanding and improving key determinants of pharmacological properties.

Journal: Bioorganic & medicinal chemistry letters
Published: April 04, 2016

The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction.

The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction.

Journal: Journal of hepatology
Published: October 05, 2015

Knocking on FXR's door: the "hammerhead"-structure series of FXR agonists - amphiphilic isoxazoles with potent in vitro and in vivo activities.

Knocking on FXR's door: the "hammerhead"-structure series of FXR agonists - amphiphilic isoxazoles with potent in vitro and in vivo activities.

Journal: Current topics in medicinal chemistry
Published: July 14, 2014

The nuclear bile acid receptor FXR controls the liver derived tumor suppressor histidine-rich glycoprotein.

The nuclear bile acid receptor FXR controls the liver derived tumor suppressor histidine-rich glycoprotein.

Journal: International journal of cancer
Published: June 06, 2014
Showing 1-12 of 16

Last Updated: 09/26/2026